Ketoconazole + Tris-Edta

Verify with FDA CVM →

19 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
3
Deaths Reported
1580.0%
Death Rate

Active Ingredients

KetoconazoleKetoconazole + Tris-EdtaTris-Edta

Administration Routes

UnknownAuricular (Otic)

Species Affected

Dog 17
Cat 2

Most Affected Breeds

Retriever - Labrador 3
Poodle (unspecified) 3
Poodle - Toy 2
Domestic Shorthair 2
Corso Dog 1
Schipperke 1
Shepherd Dog - Australian 1
Bulldog (unspecified) 1
Shepherd Dog (unspecified) 1
Bulldog - American 1

Most Reported Reactions

Lack of efficacy (fungi) - NOS 5
Head tilt - ear disorder 4
Ear canal erythema 3
Tense abdomen 3
Ataxia 3
Balance problem 3
Lack of efficacy - NOS 3
Icterus 2
Other abnormal test result NOS 2
Ear infection NOS 2
Bradycardia 2
Abnormal posture 2

Outcome Breakdown

Outcome Unknown
6 (31.6%)
Recovered/Normal
6 (31.6%)
Ongoing
3 (15.8%)
Euthanized
2 (10.5%)
Recovered with Sequela
1 (5.3%)
Died
1 (5.3%)

Data Summary

Metric Value
Total adverse event reports 19
Reports involving death 3
Case-fatality rate (reported events) 1580.0%
Distinct species in reports 2
Distinct breeds in reports 13
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Ketoconazole + Tris-Edta Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 19 adverse event reports referencing Ketoconazole + Tris-Edta, including 3 reports in which the animal died — a 1580.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Ketoconazole, Ketoconazole + Tris-Edta, Tris-Edta. Reported administration routes include Unknown, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Ketoconazole + Tris-Edta reports are Dog (17 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (3), Poodle (unspecified) (3), Poodle - Toy (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Ketoconazole + Tris-Edta are Lack of efficacy (fungi) - NOS (5), Head tilt - ear disorder (4), Ear canal erythema (3), Tense abdomen (3). Of the 19 reports with a coded outcome, Outcome Unknown is the leading category at 31.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Ketoconazole + Tris-Edta.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial